← Back to headlines
RBC Capital Lifts Price Target for Incyte Corporation
RBC Capital has raised its price target for Incyte Corporation (INCY) from $92 to $95. This upward adjustment reflects a more positive financial outlook for the biopharmaceutical company.
20 Apr, 00:08 — 20 Apr, 00:08
Sources
Showing 1 of 1 sources
